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database. Baseline demographics, HbA1C, co-morbidities, health
care utilization, pharmacy copayment, and concomitant fol-
lowup antidiabetic medications were controlled. Costs were
evaluated using actual paid claims by health insurance, adjusting
for inﬂation to the most current year value. RESULTS: Patients at
baseline had same mean age 54 years, 44 vs. 52% female, base-
line HbA1C 9.3 vs. 8.9%, access to endocrinologist 36 vs. 46%,
average number of oral antidiabetic agents 2.3 vs. 2.0, patients
with medical insurance claims for hypoglycemia 3.2 vs. 4.3%,
Charlson comorbidity score for overall comorbidities 0.64 vs.
0.82, and 6-month total health care costs $8,797 vs. $12,924 in
glargine vs. NPH initiator groups, respectively. Adjusted 1-year
mean HbA1C was 8.05 vs. 8.51% (d = -0.45, p = 0.0036) and
2-year mean HbA1C was 8.03 vs. 8.37% (d = -0.33, p = 0.0099)
for glargine and NPH, respectively. At end of 2 years, 16.6%
NPH initiators dispensed glargine prescriptions while 2.7%
glargine initiators dispensed NPH prescriptions. Adjusted rate
of patients per quarter in the ﬁrst year with medical claims
for hypoglycemia was 1.7 vs. 2.9% (d = -1.2%, p = 0.0559)
and 2-year quarterly rate was 1.55 vs. 2.51% (d = -0.96%,
p = 0.0139). Adjusted 1-year total health care costs were
$16,184 vs. $21,104 (quarterly d = -$1,034, p = 0.0372) and
2-year costs was $30,032 vs. $42,208 (quarterly d = -$1,522,
p = 0.0029). CONCLUSION: Initiation of insulin glargine, rela-
tive to NPH, was associated with sustained improvements in
glycemic control with lower rate of medically claimed hypogly-
cemia and lower total health care expenditures in patients with
T2DM.
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OBJECTIVES: To compare 1-year health care utilization and
costs in patients initiating insulin glargine vs NPH. METHODS:
Patients with T2DM (03/2001..C03/2005) who failed oral agents
and initiated insulin glargine or NPH were evaluated using
the Integrated Health Care Information System, a US managed
care health plan database. Patients were continuously enrolled
with managed care health plans for °Ý6 months before and
12 months after insulin initiation. Propensity score matched
NPH to glargine initiators by baseline demographics, HbA1c,
co-morbidities, health care utilization, and pharmacy copay-
ment. Conditional logistic regression, McNemar’s test, and
paired t-test were used to compare subsequent utilizations/ costs
between two insulin groups. Costs were paid by health insurance,
adjusting for inﬂation to the most current year value in database.
RESULTS: Matched sample (n = 1,468) was 46% female, mean
age 54.6 yrs., A1C 9.2%, Charlson Comorbidity Index (CCI)
0.69, metformin-use 77.6%, sulfonylureas 77.6%, and thiazo-
lidinedione 56%. Before matching, glargine initiators were more
likely than NPH initiators to be female, had higher HbA1c, CCI,
more use of TZD, sulfonylurea and statins, fewer visits to an
endocrinologist, higher out-of-pocket drug copayment, lower
total health care utilization and associated costs (except diabetes
medications). After propensity score matching, no differences
remained between matched pairs. During 12-month follow-up,
glargine initiators showed a lower hospitalization rate (OR:0.73,
95%CI [0.57–0.94], P = 0.0124) while outpatient and emer-
gency service utilization was not statistically different between
groups. Number needed to treat with glargine was 17 (95% CI:
9–59) to avoid hospitalization for a patient. For the same
follow-up period, glargine use on average cost $532 vs. $293 for
NPH (P < 0.0001) and $2097 vs $1820 for all antidiabetic
medications (P < 0.0001). CONCLUSION: Initiation of insulin
glargine is associated with lower rate of hospitalization com-
pared to NPH in individuals with T2DM. This clinical beneﬁt is
achieved with a modest increase in pharmacy expenditures for
treating diabetes.
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OBJECTIVES: Despite extensive use of basal-bolus and pre-
mixed analog insulin therapy, real-world comparative effective-
ness of the regimens has not been determined. METHODS:
Patients with Type 2 diabetes at two US endocrinology practice
centers were randomized to insulin glargine plus glulisine
(GLAR/GLU, n = 106) or analog premix (n = 91). Subsequent to
randomization, patients continued treatment following center’s
usual practice with no additional therapeutic protocols. Data
collected at 0, 3, 6 and 9 months included A1C, hypoglycemia,
insulin dose, concomitant medications, and therapy change.
Medication costs were estimated using published average whole-
sale price. RESULTS: Treatment groups were comparable at
baseline with mean age 56 years, 46% male, 59% Caucasian,
and 38% African-American, duration of diabetes 13 years,
HbA1C 9.25%, and BMI 35.8 kg/m2. About 70% patients used
oral hypoglycemic agent(s) during 4 months before randomiza-
tion, 88% used insulin with mean daily dose of 71IU, and 29%
had chart records for hypoglycemia. Mean follow-up time was
183 days. 1 patient (1%) randomized to GLAR/GLU switched
to premix therapy relative to 9 (10%) randomized to premix
switched to GLAR/GLU. In ITT analysis, adjusted mean
follow-up HbA1C was 6.98% in GLAR/GLU vs. 7.57% in
premix (d = -0.59%, p = 0.009) and HbA1C reduction was
2.27% (95% CI: 1.63–2.91) vs. 1.68% (1.20–2.16). Mean
number of concomitant oral anti-diabetic agents were 0.94 vs.
1.22 (d = -0.28, p = 0.041). Mean daily insulin dose was 74IU
vs. 85IU (d = -11, p = 0.267). Hypoglycemia was recorded in
charts for 36% vs. 43% (d = -7%, p = 0.374) patients in GLAR/
GLU vs. premix. Daily costs for all anti-diabetic medications
were $9.8 in GLAR/GLU vs. $11.9 in premix (d = -$2.1,
p = 0.036). Treatment costs per 1% HbA1C reduction during
follow-up period (183 days) were $790 for GLAR/GLU vs.
$1,296 for premix. CONCLUSION: In real world practices,
glargine plus glulisine, relative to analogue premix, produces
improved glycemic control with lower total diabetes medication
costs.
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OBJECTIVES: Diabetes, hypertension and high cholesterol are
all prevalent in the United States. The purpose of this research is
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